© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Key Advances in Oral Therapies for Psoriasis Unveiled at Winter Clinical Dermatology Conference 2025
February 15, 2025
April Armstrong, MD, discussed the latest data on apremilast, deucravacitinib, and emerging TYK2 and IL-23 inhibitors at Midwinter Hawaii.
Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose
February 14, 2025
Your daily dose of the clinical news you may have missed.
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose
February 13, 2025
Your daily dose of the clinical news you may have missed.
Postnatal Antibiotics for Maternal Indications May Heighten Childhood Asthma Risk
February 12, 2025
AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.
AAAAI 2025: Omalizumab Shows Favorable Outcomes Versus Oral Immunotherapy in Multi‐Food Allergy Treatment
February 12, 2025
In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.
Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose
February 12, 2025
Your daily dose of the clinical news you may have missed.
Investigational Cell Therapy Cuts Insulin Dependency in Late-Stage Type 2 Diabetes
February 11, 2025
CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from a pilot study in T2D.
New Biomarkers Identified for Early Detection of Alzheimer Disease
February 11, 2025
Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.
Heart Disease Remains Leading Cause of Death in US: Daily Dose
February 11, 2025
Your daily dose of the clinical news you may have missed.
FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis
February 10, 2025
Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.